MCID: CLR023
MIFTS: 98

Colorectal Cancer

Categories: Genetic diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 53 37 12 71 36 28 13 13 51 40 14 69 59
Colon Cancer 53 12 71 28 51 14
Colon Carcinoma 12 51 14 69
Colorectal Carcinoma 12 51 69
Colorectal Cancer, Somatic 53 13
Colon Cancer, Somatic 53 13
Colorectal Neoplasms 41 69
Carcinoma of Colon 12 28
Colonic Neoplasms 41 69
Crc 53 71
Colonic Adenoma Recurrence, Reduced Risk of 53
Colorectal Cancer, Susceptibility to 53
Colon Cancer, Advanced, Somatic 53
Colon Cancer, Susceptibility to 53
Malignant Tumor of Colon 69
Colonic Carcinoma 12

Characteristics:

OMIM:

53
Inheritance:
autosomal dominantly acting oncogene plus loss of suppressor gene(s)


Classifications:



Summaries for Colorectal Cancer

PubMed Health : 59
About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. Colorectal cancer is cancer of the colon (the large intestine, also called the large bowel) and the rectum. Cancer of the small intestine is very rare.Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But not all polyps will become cancerous – and if they do, the process can take many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps.Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will largely depend on the stage of the cancer. For early-stage colorectal cancer, the tumor just needs to be surgically removed. At advanced stages additional treatments may be considered, such as chemotherapy or radiation therapy.In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make the transition back to the workplace easier.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and familial colorectal cancer, and has symptoms including renal cell carcinoma, neoplasm of the stomach and transitional cell carcinoma of the bladder. An important gene associated with Colorectal Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 53 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

UniProtKB/Swiss-Prot : 71 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

MedlinePlus : 40 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

Wikipedia : 72 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 35.2 APC BRAF CTNNB1 MLH1 MLH3 TP53
2 familial colorectal cancer 35.1 APC BRAF MLH1 PTPRJ TP53
3 familial adenomatous polyposis 34.3 APC AXIN2 CTNNB1 MCC MLH1 TP53
4 polyposis syndrome, hereditary mixed, 1 34.0 APC MLH1
5 mismatch repair cancer syndrome 33.7 APC CTNNB1 MLH1
6 adenoma 33.0 APC AXIN2 BRAF CTNNB1 MLH1 TP53
7 familial adenomatous polyposis 1 32.8 APC CTNNB1
8 endometrial cancer 32.4 BAX BRAF CTNNB1 MLH1 MLH3 PIK3CA
9 breast cancer 32.4 APC AXIN2 BAX CTNNB1 EP300 MLH1
10 gastric cancer 32.3 APC BAX CTNNB1 MLH1 PIK3CA TP53
11 adenocarcinoma 32.3 BRAF CTNNB1 FGFR3 MLH1 TP53
12 colon adenocarcinoma 32.3 BAX CTNNB1 MLH1
13 ovarian cancer 32.1 BAX BRAF CTNNB1 MLH1 PIK3CA TP53
14 colorectal adenoma 32.1 CTNNB1 MLH1 TP53
15 hepatocellular carcinoma 31.9 APC BAX CTNNB1 DLC1 PDGFRL PIK3CA
16 colonic benign neoplasm 31.9 APC AXIN2 BAX BRAF CTNNB1 DCC
17 hyperplastic polyposis syndrome 31.8 APC BRAF TP53
18 colorectal adenocarcinoma 31.6 BRAF CTNNB1 MLH1 TP53
19 esophageal cancer 31.5 BAX CTNNB1 DCC PIK3CA TP53
20 peutz-jeghers syndrome 31.3 APC CTNNB1 TP53
21 uterine carcinosarcoma 31.1 CTNNB1 PIK3CA TP53
22 endometrial adenocarcinoma 31.0 CTNNB1 MLH1 TP53
23 li-fraumeni syndrome 30.9 BAX MLH1 TP53
24 colorectal cancer 1 12.4
25 colorectal cancer 3 12.4
26 colorectal cancer 10 12.4
27 colorectal cancer, hereditary nonpolyposis, type 5 12.4
28 colorectal cancer, hereditary nonpolyposis, type 8 12.4
29 colorectal cancer, hereditary nonpolyposis, type 6 12.4
30 colorectal cancer, hereditary nonpolyposis, type 4 12.4
31 colorectal cancer 12 12.3
32 colorectal cancer, hereditary nonpolyposis, type 7 12.3
33 oligodontia-colorectal cancer syndrome 12.3
34 colorectal cancer, hereditary nonpolyposis, type 2 12.3
35 colorectal cancer 2 12.2
36 colorectal cancer 5 12.2
37 lynch syndrome i 12.2
38 adenosquamous colon carcinoma 12.2
39 familial colorectal cancer type x 12.1
40 medullary colon carcinoma 12.1
41 transverse colon cancer 12.1
42 ascending colon cancer 12.1
43 descending colon cancer 12.1
44 colon carcinoma in situ 12.1
45 colorectal cancer 8 12.1
46 colorectal cancer 6 12.1
47 colorectal cancer 7 12.1
48 colorectal cancer 9 12.1
49 colorectal cancer 11 12.1
50 colorectal cancer, childhood 12.0

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectal Neoplasm
Rectosigmoid Junction Neoplasm Small Intestine Cancer
Splenic Flexure Cancer Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Symptoms via clinical synopsis from OMIM:

53
Oncology:
hereditary nonpolyposis colorectal carcinoma
associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma
apc, ras, dcc or kras gene mutations
allele loss on chromosomes 5, 6, 12q, 15, 17, 18, or 22


Clinical features from OMIM:

114500

Human phenotypes related to Colorectal Cancer:

31
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584
2 neoplasm of the stomach 31 HP:0006753
3 transitional cell carcinoma of the bladder 31 HP:0006740
4 uterine leiomyosarcoma 31 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 31 HP:0006716

UMLS symptoms related to Colorectal Cancer:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 BAX BRAF EP300 MLH1 MLH3 RAD54B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 BAX DCC MLH1 PDGFRL RAD54B TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 BAX BRAF DCC MLH1 PDGFRL RAD54B

MGI Mouse Phenotypes related to Colorectal Cancer:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AXIN2 APC BAX CTNNB1 DLC1 BRAF
2 mortality/aging MP:0010768 10.44 AXIN2 APC BAX CTNNB1 DLC1 BRAF
3 growth/size/body region MP:0005378 10.42 AXIN2 APC BAX CTNNB1 BRAF FLCN
4 hematopoietic system MP:0005397 10.4 APC BAX CTNNB1 BRAF DCC DLC1
5 embryo MP:0005380 10.37 AXIN2 APC CTNNB1 BRAF DLC1 EP300
6 cardiovascular system MP:0005385 10.36 AXIN2 APC CTNNB1 BRAF EP300 FLCN
7 homeostasis/metabolism MP:0005376 10.36 BAX APC CTNNB1 BRAF EP300 FLCN
8 immune system MP:0005387 10.35 APC BAX DCC CTNNB1 BRAF FLCN
9 endocrine/exocrine gland MP:0005379 10.32 AXIN2 APC BAX CTNNB1 BRAF EP300
10 neoplasm MP:0002006 10.29 BRAF APC BAX CTNNB1 DCC FGFR3
11 nervous system MP:0003631 10.27 AXIN2 APC BAX DCC CTNNB1 BRAF
12 craniofacial MP:0005382 10.26 AXIN2 APC CTNNB1 BRAF DLC1 FGFR3
13 digestive/alimentary MP:0005381 10.2 APC DCC CTNNB1 BRAF EP300 FGFR3
14 muscle MP:0005369 10.1 BAX APC CTNNB1 BRAF EP300 TP53
15 normal MP:0002873 10.1 AXIN2 APC CTNNB1 BRAF MCC DLC1
16 limbs/digits/tail MP:0005371 10.07 APC BAX AXIN2 CTNNB1 FGFR3 TP53
17 hearing/vestibular/ear MP:0005377 10.04 APC BAX CTNNB1 BRAF FGFR3 TP53
18 no phenotypic analysis MP:0003012 10.03 AXIN2 APC CTNNB1 FGFR3 TP53 PIK3CA
19 reproductive system MP:0005389 10.03 AXIN2 APC BAX CTNNB1 BRAF FGFR3
20 renal/urinary system MP:0005367 9.92 BAX APC CTNNB1 BRAF EP300 FLCN
21 pigmentation MP:0001186 9.85 APC DCC CTNNB1 BRAF SRC TP53
22 respiratory system MP:0005388 9.85 BAX DCC CTNNB1 BRAF FGFR3 EP300
23 skeleton MP:0005390 9.61 APC BAX AXIN2 CTNNB1 BRAF FGFR3
24 vision/eye MP:0005391 9.4 AXIN2 BRAF APC BAX CTNNB1 DCC

Drugs & Therapeutics for Colorectal Cancer

PubMedHealth treatment related to Colorectal Cancer: 59

Surgery is performed to remove as much of the cancer as possible. In some cases, no further treatment is needed for early-stage tumors. If the cancer is at a more advanced stage, treatments like radiation therapy or chemotherapy are options.

FDA approved drugs:

(show all 12)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Avastin 17 45 BEVACIZUMAB Genentech July 2009
2
Campostar 17 45 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 17 Immunomedics April 1996
4
Eloxatin 17 45 OXALIPLATIN Sanofi-aventis August 2002
5
Erbitux 17 45 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
6
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
7
Iressa 17 45 GEFITINIB AstraZeneca May 2003
8
Stivarga 17 45 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
9
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
10
Vectibix 17 45 PANITUMUMAB Amgen September 2006
11
Xeloda 17 45 CAPECITABINE Roche April 1998/ May 2001
12
Zaltrap 17 45 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 911)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
2
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
3
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 17902-23-7 5386
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
6
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
7
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112887-68-0 104758
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
9
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
10
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
11
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
12
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1 7553-56-2 807
13
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
14
Iron Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7439-89-6 23925
15
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2 114-07-8 12560
16
Bisacodyl Approved Phase 4,Phase 3 603-50-9
17
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
18
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
19
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
20
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 169590-42-5 2662
21
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 46507594 772
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 437-38-7 3345
23
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
24
Propofol Approved, Investigational, Vet_approved Phase 4,Early Phase 1 2078-54-8 4943
25
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38396-39-3, 2180-92-9 2474
26
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 175805 71273
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
29
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
30
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
31
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
32
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1 2216-51-5 16666
33
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051 23994
34
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
35
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
36
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
37 Magnesium citrate Approved Phase 4,Phase 3
38
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
39
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
40
Udenafil Approved, Investigational Phase 4,Phase 2 268203-93-6 6918523
41
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
42 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1 329-65-7
43
Ranibizumab Approved Phase 4,Phase 3 347396-82-1 459903
44
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 6400441 383414
45
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
46
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
47
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
48
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 93-14-1 3516
49
Methadone Approved Phase 4,Phase 1,Phase 2 76-99-3 4095
50
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 1 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 5023)

# Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
3 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
4 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
5 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
6 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
7 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
8 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
9 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
10 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
11 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
12 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
13 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
14 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
15 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
16 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
17 Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery Unknown status NCT01797770 Phase 4 polyethylene glycol
18 Glucagon and Colonoscopy Unknown status NCT02078726 Phase 4 Glucagon;Placebo
19 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
20 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
21 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
22 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
23 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
24 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
25 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
26 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
27 Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients Completed NCT01732783 Phase 4
28 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
29 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
30 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
31 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
32 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
33 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
34 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
35 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
36 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
37 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
38 Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Completed NCT01493713 Phase 4
39 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4
40 CHOICE: Communicating Health Options Through Information and Cancer Education Completed NCT00134589 Phase 4
41 A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
42 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
43 Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants Completed NCT00138060 Phase 4 irinotecan;5 fluorouracil
44 Nutrition for Colorectal Cancer Patients and Neutrophil Functions Completed NCT01831310 Phase 4
45 Chemotherapy Combined With CIK Treating Colon Cancer Completed NCT03084809 Phase 4 Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
46 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
47 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4 Capecitabine
48 Inflammatory Response in Laparoscopic and Open Colectomy Completed NCT00942461 Phase 4
49 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
50 Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT Completed NCT00654212 Phase 4

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 28 AKT1 APC AXIN2 BUB1B CTNNB1 DCC DLC1 EP300 FGFR3 FLCN NRAS PIK3CA SRC TP53
2 Colon Cancer 28
3 Colorectal Cancer 28

Anatomical Context for Colorectal Cancer

MalaCards organs/tissues related to Colorectal Cancer:

38
Colon, Liver, Testes, Breast, Lung, Lymph Node, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

18
The Rectum, The Colon

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 10907)
# Title Authors Year
1
Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. ( 29327160 )
2018
2
Tumor-suppressive miR-145 co-repressed by TCF4-I^-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer. ( 28921929 )
2018
3
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
4
Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis. ( 29448935 )
2018
5
Does the number of operating specialists influence the conversion rate and outcomes after laparoscopic colorectal cancer surgery? ( 29442241 )
2018
6
G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. ( 28875496 )
2018
7
Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. ( 29112225 )
2018
8
NIT1 suppresses tumour proliferation by activating the TGFI^1-Smad2/3 signalling pathway in colorectal cancer. ( 29449642 )
2018
9
Fecal immunochemical tests in combination with blood tests for colorectal cancer and advanced adenoma detection-systematic review. ( 29435309 )
2018
10
miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein. ( 29386092 )
2018
11
PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. ( 29449544 )
2018
12
Prepared for surgery-Communication in nurses' pre-operative consultations with patients undergoing surgery for colorectal cancer after a person-centred intervention. ( 29446494 )
2018
13
Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study. ( 29304532 )
2018
14
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( 29450468 )
2018
15
Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. ( 29179614 )
2018
16
Epigenetic silencing of<i>SMOC1</i>in traditional serrated adenoma and colorectal cancer. ( 29435136 )
2018
17
Short- and long-term outcomes following laparoscopic<i>vs</i>open surgery for pathological T4 colorectal cancer: 10 years of experience in a single center. ( 29358884 )
2018
18
Colorectal Cancer-Associated Genes Are Associated with Tooth Agenesis and May Have a Role in Tooth Development. ( 29445242 )
2018
19
Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. ( 29450632 )
2018
20
Tri-Layer Polymeric Shells containing Magnetite Nanocarrier mediated LCS-1 delivery for Synthetic Lethal Therapy of BLM-defective Colorectal Cancer Cells. ( 29451980 )
2018
21
Risk of colorectal cancer in patients with periodontal disease severity: a nationwide, population-based cohort study. ( 29397431 )
2018
22
Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. ( 29452346 )
2018
23
Insulin receptor substrate-4 is overexpressed in colorectal cancer and promotes retinoblastoma-cyclin-dependent kinase activation. ( 29353348 )
2018
24
Response to letter to editor regarding published article-metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. ( 29450672 )
2018
25
Infective endocarditis in a patient with metastatic colorectal cancer. ( 29390605 )
2018
26
Screening in spouses of colorectal cancer patients: a missed opportunity. ( 29450635 )
2018
27
Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients. ( 29277790 )
2018
28
Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae. ( 29445866 )
2018
29
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells. ( 29277783 )
2018
30
Prognostic Significance of Mitochondrial Transcription Factor A Expression in Patients with Right- or Left-sided Colorectal Cancer. ( 29277826 )
2018
31
DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus. ( 29446085 )
2018
32
Coffee drinking and colorectal cancer and its subsites: A pooled analysis of 8 cohort studies in Japan. ( 29446077 )
2018
33
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. ( 29115526 )
2018
34
Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. ( 29445100 )
2018
35
Downregulation of LncRNA-RP11-317J10.2 promotes cell proliferation and invasion and predicts poor prognosis in colorectal cancer. ( 29073791 )
2018
36
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. ( 29445027 )
2018
37
PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer. ( 28619512 )
2017
38
BRG1 promotes VEGF-A expression and angiogenesis in human colorectal cancer cells. ( 28899659 )
2017
39
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. ( 27914787 )
2017
40
Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. ( 28423626 )
2017
41
Increased expression of interleukin-21 along colorectal adenoma-carcinoma sequence and its predicating significance in patients with sporadic colorectal cancer. ( 28887120 )
2017
42
Clinical Significance of Methylation and Reduced Expression of the Quaking Gene in Colorectal Cancer. ( 28179294 )
2017
43
SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer. ( 28088387 )
2017
44
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. ( 28880972 )
2017
45
The BAX gene as a candidate for negative autophagy-related genes regulator on mRNA levels in colorectal cancer. ( 28035578 )
2017
46
Gab3 is required for human colorectal cancer cell proliferation. ( 28115166 )
2017
47
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status. ( 28870917 )
2017
48
Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer. ( 28304185 )
2017
49
Proteomics analysis of differential protein expression identifies heat shock protein 47 as a predictive marker for lymph node metastasis in patients with colorectal cancer. ( 27925182 )
2017
50
Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7. ( 28435295 )
2017